Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"novel transcript, antisense to NBPF20" (ENSG00000303361) refers to a long non-coding RNA gene annotated in the human genome that is antisense to the NBPF20 protein-coding gene. It does not encode a protein and is not described in major functional, disease, or drug-target databases. There is insufficient published evidence to support any role as a therapeutic target, biomarker, or disease-gene. It is likely an annotation for a putative lncRNA, detected by computational transcriptome analysis rather than experimental validation[3]. The actual NBPF20 gene (NBPF member 20) is a protein-coding gene, unrelated to this antisense lncRNA, and is found as ENSG00000162825[1][2][5][6][7][8]. Therefore, if you intended an actual target for therapeutic or drug discovery purposes, ENSG00000303361 is not appropriate, and the correct entry would be NBPF20 (ENSG00000162825)[1][2][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on novel transcript, antisense to NBPF20.